A Phase II Window Evaluation of the Farnesyl Transferase Inhibitor (R115777) Followed by 13-CIS Retinoic Acid, Cytosine Arabinoside and Fludarabine Plus Hematopoietic Stem Cell Transplantation in Children With Juvenile Myelomonocytic Leukemia.

Trial Profile

A Phase II Window Evaluation of the Farnesyl Transferase Inhibitor (R115777) Followed by 13-CIS Retinoic Acid, Cytosine Arabinoside and Fludarabine Plus Hematopoietic Stem Cell Transplantation in Children With Juvenile Myelomonocytic Leukemia.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 01 Apr 2015

At a glance

  • Drugs Tipifarnib (Primary) ; Antithymocyte globulin; Cyclophosphamide; Cytarabine; Fludarabine; Isotretinoin
  • Indications Myeloid leukaemia
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Most Recent Events

    • 16 Jan 2013 Primary endpoint added as reported by ClinicalTrials.gov.
    • 14 Jul 2009 New source identified and integrated (New Jersey Cancer Trial Connect).
    • 18 Jan 2007 Status change from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top